Endologix, Inc. (NASDAQ:ELGX)’s stock price shot up 5.3% on Tuesday . The stock traded as high as $6.88 and last traded at $6.80, 476,221 shares were traded during trading. An increase of 98% from the average session volume of 240,139 shares. The stock had previously closed at $6.46.

Several research firms recently weighed in on ELGX. Zacks Investment Research lowered shares of Endologix from a “buy” rating to a “hold” rating in a report on Wednesday, July 24th. Royal Bank of Canada set a $7.00 target price on shares of Endologix and gave the company a “hold” rating in a report on Friday. Finally, ValuEngine upgraded shares of Endologix from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. One investment analyst has rated the stock with a sell rating, six have given a hold rating and one has given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $20.25.

The company has a debt-to-equity ratio of 11.12, a quick ratio of 0.90 and a current ratio of 1.58. The firm has a market cap of $107.23 million, a price-to-earnings ratio of -0.94 and a beta of 0.37. The company’s fifty day simple moving average is $6.84.

Endologix (NASDAQ:ELGX) last posted its earnings results on Thursday, August 8th. The medical instruments supplier reported ($0.37) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.80) by $0.43. The business had revenue of $36.24 million for the quarter, compared to analyst estimates of $36.09 million. Endologix had a negative net margin of 60.32% and a negative return on equity of 154.23%. As a group, research analysts expect that Endologix, Inc. will post -3.23 earnings per share for the current year.

Institutional investors have recently added to or reduced their stakes in the stock. HighTower Advisors LLC bought a new position in Endologix during the second quarter worth $145,000. Parametric Portfolio Associates LLC boosted its position in Endologix by 204.5% during the second quarter. Parametric Portfolio Associates LLC now owns 57,709 shares of the medical instruments supplier’s stock worth $418,000 after purchasing an additional 38,758 shares during the period. Northern Trust Corp boosted its position in Endologix by 11.8% during the second quarter. Northern Trust Corp now owns 137,879 shares of the medical instruments supplier’s stock worth $998,000 after purchasing an additional 14,590 shares during the period. Renaissance Technologies LLC boosted its position in Endologix by 868.3% during the second quarter. Renaissance Technologies LLC now owns 613,906 shares of the medical instruments supplier’s stock worth $4,445,000 after purchasing an additional 550,506 shares during the period. Finally, M&T Bank Corp bought a new position in Endologix during the second quarter worth $102,000. 48.44% of the stock is currently owned by hedge funds and other institutional investors.

Endologix Company Profile (NASDAQ:ELGX)

Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system.

See Also: Do back-end load funds outperform no-load funds?

Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.